Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors

Fig. 3

Anti-tumor activity of The-0504 in PaCa44 or MDA-MB-231 tumor-bearing mice. a, b Tumor-growth curves for each mouse group are indicated. Student’s t-test was used to determine statistical significance. a Control vs The-0504 0.95 mg/Kg: **p < 0.005; Control vs The-0504 1.9 mg/Kg: ***p < 0.0001; Control vs Genz-644282: *p < 0.05; Genz-644282 vs The-0504 1.9 mg/Kg: *p < 0.05. b Control vs The-0504: ***p < 0.0001; Genz-644282 vs The-0504 1.9 mg/Kg: **p < 0.005. c, d Survival curves of different animal groups. Mice were sacrificed when the tumor had reached a volume in the range 1000–1500 mm3. Statistical analysis was performed by log-rank test. C Control vs The-0504 0.95 mg/Kg, Control vs The-0504 1.9 mg/Kg and Control vs Genz-644282: **p < 0.005; Genz-644282 vs The-0504 0.95 mg/Kg: *p < 0.05; Genz-644282 vs The-0504 1.9 mg/Kg: **p < 0.005. d Control vs The-0504: **p < 0.005; Genz-644282 vs The-0504: **p < 0.005. Arrows indicate the six days during which treatments were administered

Back to article page